161.12 0.00 (0.00%)
After hours: 4:15PM EDT
|Bid||161.62 x 800|
|Ask||161.64 x 800|
|Day's Range||159.25 - 162.87|
|52 Week Range||108.85 - 177.99|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||45.73|
|Forward Dividend & Yield||1.56 (0.97%)|
|Ex-Dividend Date||May 13, 2020|
|1y Target Est||N/A|
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Based on a brief questionnaire remotely filled by the patient, the MaskSelector tool recommends the best suitable ResMed (RMD) mask for patients.
Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and robust demand for its critical care products.
ResMed cleared 166.05 cup-with-handle buy point. The company makes sleep apnea products. Some of its products may help coronavirus patients. RMD reported 45% earnings growth on April 30, fourth straight quarter of acceleration.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
U.S. weapons makers have teamed up with medical device companies to increase the supply of ventilators that can be used to combat the coronavirus pandemic, people working on the project said. The two groups do not regularly partner on projects, but when a defense industry consultant with an engineering background realized weapons makers could help solve supply-chain problems within the U.S. ventilator industry, the creation of Vent Connect was set in motion and is set to be announced on Monday, the people said. The idea gathered momentum when industry associations like the Aerospace Industries Association, which represents plane makers and defense contractors including Lockheed Martin Corp and General Dynamics Corp, teamed up with AdvaMed, the Advanced Medical Technology Association, whose members include vent manufacturers.
Joining me on the call today to discuss our quarterly results from various remote locations across San Diego and Sydney are CEO, Mick Farrell; and CFO, Brett Sandercock; as well as other members of management who will be available during the Q&A portion of our call. Thanks, Amy, and thank you all for joining us today.
ResMed Inc. shares rose in the extended session Thursday after the medical equipment maker topped Wall Street estimates as it ramped up its manufacturing of ventilators amid the COVID-19 pandemic. ResMed shares rose 6.2% after hours, following a 0.6% decline in the regular session to close at $155.32. The company reported fiscal third-quarter net income of $163.1 million, or $1.12 a share, compared with $105.4 million, or 73 cents a share, in the year-ago period. Adjusted earnings were $1.29 a share, compared with 89 cents a share in the year-ago period. Revenue rose to $769.5 million from $662.2 million in the year-ago quarter. Analysts surveyed by FactSet had forecast earnings of $1.03 a share on revenue of $724.1 million. "We have rapidly pivoted our business to respond by ramping up production of life support ventilators, non-invasive ventilators, and ventilation mask systems for the people who need them most, wherever they live," said Mick Farrell, ResMed chief executive, in a statement.
The medical product companies have partially mitigated the impact of the pandemic driven by the massive adoption of COVID-19 related healthcare-support products and services.
Zacks.com featured highlights include: Keysight Technologies, ResMed, Cigna and Jack Henry & Associates
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) is expected to have gained from increased adoption of flagship products and a ramped-up ventilator production capacity in Q3 amid the coronavirus pandemic.
The Senate approved a new $484 billion stimulus bill on Tuesday, marking another phase of government support and leaving many wondering how the money will be dispersed. Yahoo Finance’s Anjalee Khemlani joins The Final Round panel to break down the latest news about the coronavirus.
With operations in many countries hit by the coronavirus pandemic, ResMed has emerged as a Covid-19 fighter.
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.